Ashler Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Ashler Capital’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-41,239	Closed	-$97K	–	53
2018 Q1	$97K	Buy	+41,239	New	+$96.7K	0.01%	75

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ashler Capital's LCTX Position: Q2 2018 in Review

Ashler Capital sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 41,239 shares — an estimated $97K sold.

Ashler Capital first reported a position in LCTX in Q1 2018 and held it in 1 quarter. The position peaked at $97K in Q1 2018. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

Ashler Capital reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
Ashler Capital sold 41,239 Lineage Cell Therapeutics shares in Q2 2018, an estimated $97K.
Ashler Capital first reported a position in Lineage Cell Therapeutics in Q1 2018 and held it in 1 quarter.
Ashler Capital's Lineage Cell Therapeutics position peaked at $97K in Q1 2018.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on Ashler Capital's 13F filing for Q2 2018, filed 10 Aug 2018.